Pulmonary Arterial Hypertension Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers the Global Pulmonary Arterial Hypertension Drugs Market Size and is Segmented By Drug Class (Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5, Endothelin Receptor Antagonists, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The value is provided in (USD million) for the above segments.

Pulmonary Arterial Hypertension Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Pulmonary Arterial Hypertension (PAH) Industry Overview

The Pulmonary Arterial Hypertension Market is fragmented and competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. The leading players in the global market for Pulmonary Arterial Hypertension are - Arena Pharmaceuticals, Bayer AG, Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson (Actelion Pharmaceuticals, Ltd.), Merck & Co. Inc., Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation.

Pulmonary Arterial Hypertension (PAH) Market Leaders

  1. Bayer AG

  2. Gilead Sciences, Inc.

  3. Johnson & Johnson (Actelion Pharmaceuticals, Ltd.)

  4. Pfizer, Inc.

  5. United Therapeutics Corporation

  6. *Disclaimer: Major Players sorted in no particular order
Pulmonary Arterial Hypertension Market Concentration

Pulmonary Arterial Hypertension (PAH) Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?